News >

Expert Discusses Treatment Options in Advanced CRC

Angelica Welch
Published: Monday, Nov 13, 2017

Cathy Eng, MD

Cathy Eng, MD
There has been an ongoing conversation surrounding the use of TAS-102 as opposed to the multikinase inhibitor regorafenib (Stivarga) in patients with colorectal cancer (CRC) who have progressed on prior therapies.

Meeting, Eng, professor of gastrointestinal medical oncology at The University of Texas MD Anderson Cancer Center, discussed optimizing sequencing beyond disease progression in CRC. She also shed light on available treatments in CRC, encouraged physicians to dose adjust therapy for their patients, and highlighted studies further exploring immunotherapy in the field.

OncLive: Please provide an overview of your lecture on CRC.

Eng: I discussed what therapies are available to patients following first-line treatment, especially in the setting of progression of disease. I focused not only on the continuation of antiangiogenic agents in the second-line setting, but also the role of anti-EGFR therapy in the second- or third-line setting. Of course, there are the recent oral drugs that have been approved—regorafenib and TAS-102—in the refractory setting. I wanted to highlight some of the more recent trials that are more focused on rare subsets—specifically patients with a BRAF-mutated tumor—which is present in less than 10% of patients. It’s a very poor prognostic indicator. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication
x